Bausch Health Companies (BHC) Research & Development (2009 - 2026)

Bausch Health Companies (BHC) has 18 years of Research & Development data on file, last reported at $163.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 13.99% year-over-year to $163.0 million; the trailing twelve-month figure through Mar 2026 stood at $649.0 million (up 6.74% YoY), and the FY2025 full-year result was $629.0 million, up 2.11% from the prior year.
• Research & Development rose to $163.0 million in Q1 2026, from $161.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $166.0 million in Q3 2025 to a low of $127.0 million in Q1 2022.
• A 5-year average of $149.5 million and a median of $152.0 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development rose 22.83% in 2023 and fell 5.3% in 2025, its largest moves.
• Tracing BHC's Research & Development over 5 years: stood at $142.0 million in 2022, then rose by 7.04% to $152.0 million in 2023, then advanced by 7.24% to $163.0 million in 2024, then dropped by 1.23% to $161.0 million in 2025, then advanced by 1.24% to $163.0 million in 2026.
• Business Quant data shows BHC's Research & Development at $163.0 million in Q1 2026, $161.0 million in Q4 2025, and $166.0 million in Q3 2025.